Angiogenesis is one of the pivotal cancer hallmarks that promotes cancer growth and metastasis, including esophageal carcinoma, and is a target of biologicals such as bevacizumab, which blocks the vascular endothelial growth factor, VEGF, and drugs such as the multi-receptor tyrosine kinase inhibitors (TKIs) that target the VEGF receptor, VEGFR. Here, VEGFA is linked to carcinoma of esophagus.